

# Urgent Field Safety Notice

## SBN-RDS-CoreLab-2023-001

RDS/CoreLab/ Immunology

Version 1

January 2023

### Elecsys® Troponin T hs / Elecsys Troponin T hs STAT: discrepant elevated results with certain plasma EDTA primary tubes

<b>Product Name</b>	Elecsys Troponin T hs Elecsys Troponin T hs STAT
<b>Device Identifier GMMI / Part No / UDI</b>	Elecsys Troponin T hs ( <b>cobas</b> ® e 411, 601, 602; 200 tests) GMMI: 08469717190 UDI: 7613336001199X  Elecsys Troponin T hs STAT ( <b>cobas</b> e 411, 601, 602; 100 tests) GMMI: 08469814190 UDI: 7613336001209G  Elecsys Troponin T hs ( <b>cobas</b> e 402, 801, 300 tests) GMMI: 08469873190 UDI: 7613336001219J  Elecsys Troponin T hs ( <b>cobas</b> e 411, 601, 602; 200 tests) GMMI: 09315322190 UDI: 761333600917B3  Elecsys Troponin T hs STAT ( <b>cobas</b> e 411, 601, 602; 100 tests) GMMI: 09315349190 UDI: 761333600918B5  Elecsys Troponin T hs ( <b>cobas</b> e 402, 801; 300 tests) - GMMI: 09315357190 UDI: 761333600919B7
<b>Production Identifier (Lot No./Serial No.)</b>	n/a
<b>SW Version</b>	n/a
<b>Type of Action</b>	Field Safety Corrective Action (FSCA)

Dear Valued Customer,

#### Description of Situation

During internal studies with the Elecsys Troponin T hs (high sensitive) / Elecsys Troponin T hs STAT assay, discrepant elevated assay results were observed for K<sub>2</sub> EDTA plasma samples. Further investigation confirmed that for certain K<sub>2</sub>/K<sub>3</sub> EDTA primary tubes, TnT hs results are elevated compared to serum samples when measured from the primary tube after processing the sample according to the tube manufacturers' instructions. This observation was confirmed for tubes from several manufacturers.

The reproducibility of the falsely elevated results and the fact that not all investigated primary tubes show this phenomenon indicate that an interference mechanism caused by pre-analytical issues with the affected primary tubes is the likely root cause.

# Elecsys<sup>®</sup> Troponin T hs / Elecsys Troponin T hs STAT: discrepant elevated results with certain plasma EDTA primary tubes



In some cases, affected samples showed observable turbidity and a pellet fraction was visible after centrifugation of affected samples. In this regard, it is important to remind the users the sample handling guidance given in the Elecsys Troponin T hs /STAT assay method sheet:

## **Specimen collection and preparation**

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

K<sub>2</sub>-EDTA, K<sub>3</sub>-EDTA, Li-heparin and Na-heparin plasma.

Plasma tubes containing separating gel can be used.

Plasma (EDTA, heparin) and serum samples should not be used interchangeably.

Criterion: Slope 0.90-1.10 + coefficient of correlation  $\geq$  0.95.

Stable for 24 hours at 2-8 °C, 12 months at -20 °C ( $\pm$  5 °C). Freeze only once.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use samples and controls stabilized with azide.

Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples, calibrators and controls on the analyzers should be analyzed/measured within 2 hours.

## **Materials provided**

Based on the current status of the investigation, no general assay and/or Elecsys technology related issue was identified. No related customer complaints were received.

The root cause investigation is still ongoing to identify the exact mechanism of interference. Current results indicate that pre-analytical aspects (e.g. presence of micro-clots) are contributing to the issue.

In this situation, incorrectly elevated TnT hs concentrations were observed with specific K<sub>2</sub>-EDTA and K<sub>3</sub>-EDTA primary tubes. This can affect interpretation of the results and influence decisions regarding diagnosis and treatment. Due to the residual medical risk, customers using affected products must be informed via FSN-RDS-CoreLab-2023-001.

# Elecsys<sup>®</sup> Troponin T hs / Elecsys Troponin T hs STAT: discrepant elevated results with certain plasma EDTA primary tubes



## Actions taken by Roche Diagnostics

Current observations will be shared with the manufacturers of the primary tubes. Root cause analysis will be continued to further gain understanding of the underlying interference mechanisms and if needed to define corrective and preventive measures.

## Actions to be taken by customers/users

Customers using K<sub>2</sub>/K<sub>3</sub> EDTA plasma for TnT hs quantification are required to (temporarily) perform the following additional preanalytical measure:

**Re-centrifuge K<sub>2</sub>/K<sub>3</sub> EDTA plasma samples in a secondary tube for 5 min at 3'000 x g or 30 sec at 10'000 x g prior to measurement.**

**This action is required until further notice.**

This additional preanalytical measure has been assessed by Roche internally and was proven effective with the samples tested.

Note: Any specific questions regarding impacted results raised by the customers should be investigated individually, considering all relevant information. Customers are advised to consult their facility's physician and/or pathologist to determine any clinical implications (including retrospective review and/or re-testing) specific to their patients.

**The following statement is mandatory in FSNs for EEA countries but is not required for the rest of the World:**

*Include if applicable:* The undersigned confirms that this notice has been notified to the appropriate Regulatory Agency.

We apologize for any inconvenience this may cause and hope for your understanding and your support.

<closing salutations>,

### Contact Details

*To be completed locally:*

Name

Title

Company Name

Address

Tel. +xx-xxx-xxxx xxxx

Email name@roche.com

Roche Diagnostics GmbH (SRN DE-AR-000006262)